Indications for use
Capsules 75 mg and 110 mg: Primary prevention of venous thromboembolic complications in patients undergoing major orthopedic hip or knee replacement surgery.
Capsules 110 mg and 150 mg: Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as stroke or transient ischemic attack, age 75 or older, heart failure, diabetes mellitus or arterial hypertension.
Method of administration and dosage
Patients after knee replacement surgery. The recommended dose is 220 mg once a day – 2 capsules of 110 mg.
Application should be started orally 1–4 hours after the completion of the operation, 1 capsule (110 mg each ) and then continue to take 2 capsules 1 time per day, for a total of 10 days.
Patients after surgery to replace the hip joint. The recommended dose is 220 mg once a day – 2 capsules of 110 mg.
Treatment should be started orally 1–4 hours after the completion of the operation, 1 capsule (110 mg each ) and then continue to take 2 capsules 1 time per day, for a total of 28–35 days.
Known hypersensitivity to dabigatran or dabigatran etexilate or to any of the ingredients of the formulation. Severe renal dysfunction (creatinine clearance <30 ml / min). The drug is not used during pregnancy and lactation. Limited for use in children.
Doses in excess of the recommended doses increase the risk of bleeding.